Patents Assigned to GITR, Inc.
  • Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodies
    Patent number: 10570209
    Abstract: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: February 25, 2020
    Assignee: GITR, Inc.
    Inventors: L. Mary Smith, Grazyna Szymanska, Paul Ponath, Michael Rosenzweig, Jose F. Ponte
  • Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodies
    Patent number: 10030074
    Abstract: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: July 24, 2018
    Assignee: GITR, Inc.
    Inventors: L. Mary Smith, Grazyna Szymanska, Paul Ponath, Michael Rosenzweig, Jose F. Ponte
  • GITR antibodies and methods of inducing or enhancing an immune response
    Patent number: 9493572
    Abstract: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: November 15, 2016
    Assignee: GITR, Inc.
    Inventors: L. Mary Smith, Grazyna Szymanska, Paul Ponath, Michael Rosenzweig, Jose F. Ponte
  • Combination therapies employing GITR binding molecules
    Patent number: 9241992
    Abstract: The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: January 26, 2016
    Assignee: GITR, Inc.
    Inventors: Jose F. Ponte, Paul Ponath, Michael Rosenzweig
  • Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies
    Patent number: 9028823
    Abstract: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 12, 2015
    Assignee: GITR, Inc.
    Inventors: L. Mary Smith, Grazyna Szymanska, Paul Ponath, Michael Rosenzweig, Jose F. Ponte
  • COMBINATION THERAPIES EMPLOYING GITR BINDING MOLECULES
    Publication number: 20140220002
    Abstract: The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents.
    Type: Application
    Filed: November 15, 2013
    Publication date: August 7, 2014
    Applicant: GITR, INC.
    Inventors: Jose F. Ponte, Paul Ponath, Michael Rosenzweig
  • Combination therapies employing GITR binding molecules
    Patent number: 8591886
    Abstract: The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: November 26, 2013
    Assignee: GITR, Inc.
    Inventors: Paul Ponath, Michael Rosenzweig, Jose F. Ponte
  • GITR BINDING MOLECULES AND USES THEREFOR
    Publication number: 20130183321
    Abstract: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.
    Type: Application
    Filed: March 1, 2013
    Publication date: July 18, 2013
    Applicant: GITR, INC.
    Inventor: GITR, INC.
  • Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies
    Patent number: 8388967
    Abstract: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: March 5, 2013
    Assignee: GITR, Inc.
    Inventors: L. Mary Smith, Grazyna Szymanska, Paul Ponath, Michael Rosenzweig, Jose F. Ponte